SCHEMBL20938254

SCHEMBL20938254

Nc1ncnc2c1c(-c1ccc(Cl)cc1Cl)cn2[C@@H]1O[C@H](CO)C[C@H]1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 6/20 0.44
▸ DOT1L Q8TEK3 1/20 0.43
▸ ABL1 P00519 2/20 0.42
▸ PRMT5 O14744 2/20 0.42
▸ EGFR P00533 1/20 0.42
▸ ABL2 P42684 1/20 0.42
▸ METTL3 Q86U44 1/20 0.42
▸ SRC P12931 9/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ NTRK1 P04629 1/20 0.42
▸ INSR P06213 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ NPM1 P06748 1/20 0.42
▸ CSF1R P07333 1/20 0.42
▸ LYN P07948 1/20 0.42
▸ RET P07949 1/20 0.42
▸ IGF1R P08069 1/20 0.42
▸ MET P08581 1/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ KIT P10721 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20920813 0.89 SRC (0.51) ADKABL1EGFRABL2SRC
SCHEMBL20938250 0.89 SRC (0.51) ADKABL1EGFRABL2SRC
SCHEMBL20938255 0.86 RIPK2 (0.58) ADKABL1EGFRABL2SRC
SCHEMBL20938268 0.86 ADK (0.50) ADKDOT1LABL1EGFRABL2
SCHEMBL20938253 0.85 ADK (0.49) ADKABL1EGFRABL2SRC
SCHEMBL20938344 0.85 ADK (0.47) ADKABL1EGFRABL2SRC
SCHEMBL20938333 0.84 ADK (0.46) ADKDOT1LPRMT5METTL3
SCHEMBL20938267 0.84 ADK (0.49) ADKABL1EGFRABL2SRC
SCHEMBL20938274 0.84 ADK (0.49) ADKABL1EGFRABL2SRC
SCHEMBL22912604 0.82 ADK (0.63) ADKABL1EGFRABL2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections UNIVERSITEIT GENT (BE) 2021-07-27 — — US disclosed
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2021-01-28 — — US disclosed
WO-2019076633-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections PNP, NUDT1, SAMHD1 ADK 109/4885DOT1L 1419/4885ABL1 1044/4885
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS PNP, NUDT1, SAMHD1 ADK 109/4885DOT1L 1419/4885ABL1 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback